Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1401603 | 0.82 | CYP1A2 (0.32) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL1401585 | 0.82 | KDM4E (0.32) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL27478746 | 0.80 | CYP1A2 (0.35) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL27857491 | 0.78 | ALDH1A1 (0.34) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL4446047 | 0.78 | CYP1A2 (0.34) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL27898545 | 0.78 | CYP1A2 (0.30) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL8945726 | 0.78 | CYP1A2 (0.30) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL379418 | 0.77 | — | — | |
| SCHEMBL8172217 | 0.77 | — | — | |
| SCHEMBL1482994 | 0.75 | CYP1A2 (0.41) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9114377-B2 | High charge density structures, including carbon-based nanostructures and applications thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150202606-A1 | HIGH CHARGE DENSITY STRUCTURES, INCLUDING CARBON-BASED NANOSTRUCTURES AND APPLICATIONS THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-07-23 | — | — | US | disclosed |
| US-8735313-B2 | High charge density structures, including carbon-based nanostructures and applications thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2014-05-27 | — | — | US | disclosed |
| WO-2010123482-A2 | HIGH CHARGE DENSITY STRUCTURES, INCLUDING CARBON-BASED NANOSTRUCTURES AND APPLICATIONS THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-10-28 | — | — | WO | disclosed |
| US-20100179054-A1 | HIGH CHARGE DENSITY STRUCTURES, INCLUDING CARBON-BASED NANOSTRUCTURES AND APPLICATIONS THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-07-15 | — | — | US | disclosed |
| EP-0138523-B1 | PENICILLIN DERIVATIVES AND PROCESS FOR PREPARING THE SAME (11111) | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1987-08-19 | — | — | EP | disclosed |
| US-4668514-A | Penicillin derivatives | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1987-05-26 | — | — | US | disclosed |
| EP-0138523-A1 | Penicillin derivatives and process for preparing the same (11111) | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1985-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179054-A1 | HIGH CHARGE DENSITY STRUCTURES, INCLUDING CARBON-BASED NANOSTRUCTURES AND APPLICATIONS THEREOF | ACP1, CA12, CNPY3 | CYP1A2 4690/4885CYP2D6 4765/4885MAPT 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.